BR112016023668A2 - hiperestimulação ovariana controlada com hormônio de estimulação de folículo humano recombinante aperfeiçoado - Google Patents

hiperestimulação ovariana controlada com hormônio de estimulação de folículo humano recombinante aperfeiçoado

Info

Publication number
BR112016023668A2
BR112016023668A2 BR112016023668A BR112016023668A BR112016023668A2 BR 112016023668 A2 BR112016023668 A2 BR 112016023668A2 BR 112016023668 A BR112016023668 A BR 112016023668A BR 112016023668 A BR112016023668 A BR 112016023668A BR 112016023668 A2 BR112016023668 A2 BR 112016023668A2
Authority
BR
Brazil
Prior art keywords
recombinant human
controlled
ovarian hyperstimulation
human follicle
improved recombinant
Prior art date
Application number
BR112016023668A
Other languages
English (en)
Inventor
Stöckl Lars
Goletz Steffen
Original Assignee
Glycotope Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Glycotope Gmbh filed Critical Glycotope Gmbh
Publication of BR112016023668A2 publication Critical patent/BR112016023668A2/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/24—Follicle-stimulating hormone [FSH]; Chorionic gonadotropins, e.g. HCG; Luteinising hormone [LH]; Thyroid-stimulating hormone [TSH]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B17/00—Surgical instruments, devices or methods, e.g. tourniquets
    • A61B17/42—Gynaecological or obstetrical instruments or methods
    • A61B17/425—Gynaecological or obstetrical instruments or methods for reproduction or fertilisation
    • A61B17/43—Gynaecological or obstetrical instruments or methods for reproduction or fertilisation for artificial insemination
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/08—Peptides having 5 to 11 amino acids
    • A61K38/09—Luteinising hormone-releasing hormone [LHRH], i.e. Gonadotropin-releasing hormone [GnRH]; Related peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0608—Germ cells
    • C12N5/0609—Oocytes, oogonia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Endocrinology (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Reproductive Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Biomedical Technology (AREA)
  • Organic Chemistry (AREA)
  • Biotechnology (AREA)
  • Wood Science & Technology (AREA)
  • Surgery (AREA)
  • Genetics & Genomics (AREA)
  • Gynecology & Obstetrics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pregnancy & Childbirth (AREA)
  • Developmental Biology & Embryology (AREA)
  • Molecular Biology (AREA)
  • Medical Informatics (AREA)
  • Cell Biology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)

Abstract

a presente invenção refere-se a métodos para a hiperestimulação ovariana controlada em um indivíduo feminino usando-se hormônio de estimulação de folículo humano recombinante aperfeiçoado (rhfsh). os métodos resultam em um alto número de ovócitos fertilizáveis mesmo em baixas quantidades de fsh administradas ao indivíduo feminino.
BR112016023668A 2014-04-18 2015-04-17 hiperestimulação ovariana controlada com hormônio de estimulação de folículo humano recombinante aperfeiçoado BR112016023668A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201461981621P 2014-04-18 2014-04-18
PCT/EP2015/058352 WO2015158875A1 (en) 2014-04-18 2015-04-17 Controlled ovarian hyperstimulation with improved recombinant human follicle-stimulating hormone

Publications (1)

Publication Number Publication Date
BR112016023668A2 true BR112016023668A2 (pt) 2017-10-17

Family

ID=53015773

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112016023668A BR112016023668A2 (pt) 2014-04-18 2015-04-17 hiperestimulação ovariana controlada com hormônio de estimulação de folículo humano recombinante aperfeiçoado

Country Status (13)

Country Link
US (1) US20170035854A1 (pt)
EP (1) EP3131571A1 (pt)
JP (1) JP2017513853A (pt)
KR (1) KR20160144480A (pt)
CN (1) CN106413735A (pt)
AR (1) AR100132A1 (pt)
AU (1) AU2015248793A1 (pt)
BR (1) BR112016023668A2 (pt)
CA (1) CA2945883A1 (pt)
IL (1) IL248362A0 (pt)
MX (1) MX2016013449A (pt)
SG (1) SG11201608132UA (pt)
WO (1) WO2015158875A1 (pt)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI488640B (zh) 2008-04-16 2015-06-21 Ferring Int Ct Sa 藥學製劑
WO2018080120A1 (en) * 2016-10-28 2018-05-03 Samsung Electronics Co., Ltd. Method and apparatus for follicular quantification in 3d ultrasound images
MA50034B1 (fr) * 2017-09-01 2022-02-28 Ferring Bv Composition de stimulation ovarienne contrôlée
CN110570952B (zh) * 2018-06-05 2022-04-12 北京大学第三医院 预测拮抗剂方案下受试者卵巢低反应概率的系统及指导促性腺激素起始用药剂量选择的系统
CN112603990B (zh) * 2020-12-17 2022-03-08 广州医药研究总院有限公司 提高犬卵巢卵丘-卵母细胞复合体数量的试剂盒及其应用
CN116798634B (zh) * 2023-08-25 2023-11-21 北京大学深圳医院 一种fsh启动剂量预测系统、电子设备及存储介质

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EA007030B1 (ru) 2001-10-22 2006-06-30 Апплайд Резеч Системз Арс Холдинг Н.В. Гонадотропины для фолликулогенеза
AU2010297580B2 (en) * 2009-09-22 2014-07-31 Probiogen Ag Process for producing molecules containing specialized glycan structures
EP2325194A1 (en) 2009-11-24 2011-05-25 Glycotope GmbH Process for the purification of glycoproteins
WO2012016576A1 (en) 2010-08-04 2012-02-09 Glycotope Gmbh Improved recombinant human follicle-stimulating hormone

Also Published As

Publication number Publication date
WO2015158875A1 (en) 2015-10-22
MX2016013449A (es) 2017-05-04
AU2015248793A1 (en) 2016-11-03
SG11201608132UA (en) 2016-11-29
IL248362A0 (en) 2016-11-30
JP2017513853A (ja) 2017-06-01
US20170035854A1 (en) 2017-02-09
KR20160144480A (ko) 2016-12-16
CA2945883A1 (en) 2015-10-22
EP3131571A1 (en) 2017-02-22
AR100132A1 (es) 2016-09-14
CN106413735A (zh) 2017-02-15

Similar Documents

Publication Publication Date Title
BR112016023668A2 (pt) hiperestimulação ovariana controlada com hormônio de estimulação de folículo humano recombinante aperfeiçoado
ZA201802657B (en) Crystal forms of beta-nicotinamide mononucleotide
GT201700072A (es) Composiciones y métodos de uso para tratar trastornos metabólicos
EA201692512A1 (ru) Способы и композиции для лечения синтетическими наноносителями и ингибиторами иммунной контрольной точки
MX2022004374A (es) Composiciones de agonista de tlr9 e inhibidores de punto de control para usarse en la respuesta inmune contra el cancer.
UY35548A (es) Péptidos terapéuticos para el tratamiento de trastornos metabólicos.
EA201890725A1 (ru) Агонисты фарнезоидного х-рецептора и их применение
BR112015021371A2 (pt) uso de agonistas de receptor de formil peptídeo 2 para tratar doenças inflamatórias oculares
BR112017009584A2 (pt) tratamento de retinite pigmentosa com n-acetilcisteína amida
BR112016022742A2 (pt) composições e métodos para modular a expressão de receptor de hormônio do crescimento
BR112017005202A2 (pt) anticorpos anti-met e composições
EP3148569A4 (en) Therapeutic tratment of skin disease with recombinant commensal skin microorganisms
EP3085410A4 (en) Skin treatment device using needle
BR112015033069A2 (pt) moduladores de receptor do hormônio de crescimento
HK1243430A1 (zh) 通過施用il-6r拮抗劑治療乾眼病的方法
BR112017002809A2 (pt) métodos para tratar câncer cervical
EP4275746A3 (en) Extracellular vesicles derived from osteoblastic lineage cells for therapeutic and diagnostic use
EP3368059A4 (en) TREATMENT OF STEROID-INDUCED HYPERGLYCEMIA WITH FIBROBLAST GROWTH FACTOR (FGF) -1 ANALOGUE
BR112017012406A2 (pt) formulação com relação fixa de insulina glargina/lixisenatida
AR100944A1 (es) ANTICUERPOS ANTAGONISTAS DE INTERFERÓN a Y w
BR112018010155A8 (pt) segmentação do receptor formil-peptídeo 2/receptor lipoxina a4 (fpr2/alx) para tratamento de doença cardíaca
BR112017004739A2 (pt) ligantes de hormônio folículo estimulante, complexo de ligante e gonadotrofina, uso de um ligante, e composição farmacêutica
BR112015028737A2 (pt) métodos para a produção e/ou purificação de hormônios
MX2015013091A (es) Metodos mejorados de uso para secretoglobinas humanas recombinantes.
BR112016023450A2 (pt) uso de compostos ctla4 para alcançar remissão livre de fármacos em indivíduos com artrite reumatoide precoce

Legal Events

Date Code Title Description
B11A Dismissal acc. art.33 of ipl - examination not requested within 36 months of filing
B11Y Definitive dismissal - extension of time limit for request of examination expired [chapter 11.1.1 patent gazette]
B350 Update of information on the portal [chapter 15.35 patent gazette]